AI US 2001-996657 A1 20011129 (9)

RLI Division of Ser. No. US 2000-740643, filed on 19 Dec 2000, PENDING

PRAI US 2000-241127P 20001017 (60)

DT Utility

FS APPLICATION

LREP THE PROCTER & GAMBLE COMPANY, PATENT DIVISION, IVORYDALE TECHNICAL

CENTER - BOX 474, 5299 SPRING GROVE AVENUE, CINCINNATI, OH, 4521

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2583

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 414866-81-2P

(drug; prepn. of piperidine derivs. useful for treating multiprus

resistance and compns. thereof)

RN 414866-81-2 USPATFULL

CN 4-Piperidinecarboxamide, 1-[2-hydroxy-3-(3,4,5-trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

IT 414866-86-7P

(drug; prepn. of piperidine derivs. useful for treating multidrug resistance and compns. thereof)

RN 414866-86-7 USPATFULL

CN 3-Piperidinecarboxamide, 1-[(2R)-2-hydroxy-3-(3,4,5-

trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 7 OF 8 USPATFULL

AB Compounds, compositions, and methods for treating multidrug resistance are disclosed. Suitable compounds are 2-substituted heterocyclic compounds. An example compound has the formula: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT. AN 2002:172362 USPATFULL 2-substituted heterocyclic compounds for treating multidrug resistance ΤI IN Degenhardt, Charles Raymond, Cincinnati, OH, UNITED STATES Eickhoff, David Joseph, Edgewood, KY, UNITED STATES ΡI US 2002091120 A1 20020711 US 2000-740279 AΙ A1 20001219 (9) PRAI US 2000-241127P 20001017 (60) DTUtility FS APPLICATION THE PROCTER & GAMBLE COMPANY, PATENT DIVISION, MIAMI VALLEY LREP LABORATORIES, P.O. BOX 538707, CINCINNATI, OH, 45253-8707 CLMN Number of Claims: 23 ECL. Exemplary Claim: 1 DRWN No Drawings LN.CNT 1700 CAS INDEXING IS AVAILABLE FOR THIS PATENT. 414866-81-2P (drug; prepn. of piperidine derivs. useful for treating multidrug resistance and compns. thereof) RN414866-81-2 USPATFULL

4-Piperidinecarboxamide, 1-[2-hydroxy-3-(3,4,5-trimethoxyphenoxy)propyl]-N-

[4-phenyl-1-(3-phenylpropyl)butyl] - (9CI) (CA INDEX NAME)

Alar Jordan

IT 414866-86-7P

CN

(drug; prepn. of piperidine derivs. useful for treating multidrug resistance and compns. thereof)

RN 414866-86-7 USPATFULL

CN 3-Piperidinecarboxamide, 1-[(2R)-2-hydroxy-3-(3,4,5-trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

MeO
$$\sim$$
 OH \sim H \sim (CH2)3 \sim Ph \sim OMe

L11 ANSWER 8 OF 8 USPATFULL

AB Substituted heterocyclic compounds are disclosed. The compounds are useful for treating multidrug resistance. The compounds can be formulated in compositions with a carrier and, optionally, a therapeutic agent. One suitable substituted heterocyclic compound has the formula: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:88498 USPATFULL

TI Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof

IN Degenhardt, Charles Raymond, Cincinnati, OH, United States Eickhoff, David Joseph, Edgewood, KY, United States

PA The Procter & Gamble Co., Cincinnati, OH, United States (U.S. corporation)

PI US 6376514 B1 20020423 AI US 2000-740643 20001219 (9)

PRAI US 2000-241127P 20001017 (60)

DT Utility FS GRANTED

EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Desai, Rita

LREP McDow-Dunham, Kelly L., Lewis, Leonard W., Clark, Karen F.

CLMN Number of Claims: 18 ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 2568

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 414866-81-2P

(drug; prepn. of piperidine derivs. useful for treating multidrug resistance and compns. thereof)

Moured Worth Remain

RN 414866-81-2 USPATFULL

CN 4-Piperidinecarboxamide, 1-[2-hydroxy-3-(3,4,5-trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

IT 414866-86-7P

(drug; prepn. of piperidine derivs. useful for treating multidrug resistance and compns. thereof)

RN 414866-86-7 USPATFULL

CN 3-Piperidinecarboxamide, 1-[(2R)-2-hydroxy-3-(3,4,5-trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

=> file caplus COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 43.03 595.30

FILE 'CAPLUS' ENTERED AT 13:05:57 ON 14 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Nov 2002 VOL 137 ISS 20 FILE LAST UPDATED: 13 Nov 2002 (20021113/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d his

(FILE 'HOME' ENTERED AT 12:32:11 ON 14 NOV 2002)

FILE 'REGISTRY' ENTERED AT 12:32:23 ON 14 NOV 2002

L1 STRUCTURE UPLOADED

L2 11 S L1

L3 8140 S L1 FUL

L4 STRUCTURE UPLOADED

L5 5 S L4

L6 2225 S L5 FUL

FILE 'USPATFULL, USPAT2' ENTERED AT 12:52:35 ON 14 NOV 2002

L7 425 S L6

FILE 'REGISTRY' ENTERED AT 13:03:20 ON 14 NOV 2002

L8 STRUCTURE UPLOADED

L9 0 S L8

L10 3 S L8 FUL

FILE 'USPATFULL, USPAT2' ENTERED AT 13:04:26 ON 14 NOV 2002

L11 8 S L10


FILE 'CAPLUS' ENTERED AT 13:05:57 ON 14 NOV 2002

=> s 110

L12 2 L10

=> d abs bib hitstr 1-2

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS GI



Title compds. I [A1 = [C(R1)2]x-D1-D2-R2; R1 = H, OH, alkyl, carbocyclic, arom. group; x = 0-10; R2 = alkyl, carbocyclic, arom. group; D1-2 = CO, NR3, with the proviso that wherein when D1 = NR3 then D2 = CO and when D2 = NR3, D1 = CO; R3 = H, R2; A3 = D4-[C(R1)2]t-D5; t = 0-6; D4 = CO, CHR1; D5 = NHR6, OR6; R6 = quinolyl] were prepd. For instance, (R)-5-oxiranylmethoxyquinoline was prepd. from (R)-glycidyl tosylate and 5-hydroxyquinoline (DMF, NaH), and used to alkylate piperidine-4-carboxylic acid [4-phenyl-1-(3-phenylpropyl)butyl]amide (prepn. given; i-PrOH, 70.degree.C, 18 h) to give II. The half-max. inhibition of MDR1-ATPase, Ki (stimulated by 30-40 .mu.M verapamil) for II = 0.3 .mu.M. I are useful for treating multidrug resistance and can be formulated optionally with a therapeutic agent, e.g., Taxol.

AN 2002:312015 CAPLUS

DN 136:325426

TI Preparation of piperidine derivatives useful for treating multidrug

```
Print selected from Online session14/11/2002
     resistance and compositions thereof
IN
     Degenhardt, Charles Raymond; Eickhoff, David Joseph
PA
     The Procter & Gamble Co., USA
SO
     U.S., 50 pp.
     CODEN: USXXAM
DT
     Patent
LA
     English
FAN.CNT 4
     PATENT NO.
                     KIND DATE
                                           APPLICATION NO.
                                                            DATE
                      ----
                                           -----
                           -----
                                                            ----
PΤ
     US 6376514
                      B1
                            20020423
                                           US 2000-740643
                                                            20001219
     US 2002082262
                      A1
                            20020627
                                           US 2000-740642
                                                            20001219
    US 2002091120
                      A1
                                           US 2000-740279
                            20020711
                                                            20001219
    US 2002115659
                      A1
                            20020822
                                           US 2000-740644
                                                            20001219
    US 2002128269
                       A1
                            20020912
                                           US 2000-740387
                                                            20001219
     WO 2002032869
                       A 2
                            20020425
                                           WO 2001-US42781 20011016
     WO 2002032969
                      A3
                            20020822
            AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,
             FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
             MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL,
             TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG,
             KZ, MD, RU, TJ
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2002099215
                      A1
                                          US 2001-996657 20011129
                            20020725
PRAI US 2000-241127P
                       Ρ
                            20001017
    US 2000-740643
                       Α
                            20001219
OS
    MARPAT 136:325426
ΙT
     414866-81-2P
    RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
    preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (drug; prepn. of piperidine derivs. useful for treating multidrug
       resistance and compns. thereof)
```

RN414866-81-2 CAPLUS

CN4-Piperidinecarboxamide, 1-[2-hydroxy-3-(3,4,5-trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl] - (9CI) (CA INDEX NAME)

IT 414866-86-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; prepn. of piperidine derivs. useful for treating multidrug

resistance and compns. thereof)

RN 414866-86-7 CAPLUS

CN 3-Piperidinecarboxamide, 1-[(2R)-2-hydroxy-3-(3,4,5trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS GI

Title compds. I (R = 4-F, H, 3,4-F2, 2,4-F2, 4-Cl, 4-Me, 3-F, 4-MeO, R1 = 4-FC6H4, Ph, 3-FC6H4, H, 2-pyridyl, etc., X = CH, CHCH2, C(OH), etc., n = 2-6), II [R2 = 2-MeO, R3 = 4-COMe, 4-CH(OH)Me, 4-Et, 4-CO2Me, etc.; R2 = 4-COMe, 4-CONH2, 4-cyano, 4-F, etc., R3 = H; Y = O, CH2, NMe, S, SO2, n = 2, 3], and III (n = 1, 2, m = 0, 1; ring position = 3, 4) were prepd. as calcium-channel blockers and antihypertensive agents. Thus, reacting Me vanillate with 4-[bis(4-fluorophenyl)methyl]-1-(3-chloropropyl)piperidine gave II (R2 = 2-MeO, R3 = 4-CO2Me, Y = 0, n = 3). The most potent compds. had fluoro substituents in the 3- and/or 4-positions of both rings of the di-Ph group.

AN 1991:583028 CAPLUS

DN 115:183028

- TI Synthesis, calcium-channel-blocking activity, and antihypertensive activity of 4-(diarylmethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds
- AU Shanklin, James R., Jr.; Johnson, Christopher P., III; Proakis, Anthony G.; Barrett, Richard J.
- CS Dep. Chem. Res., A. H. Robins Co., Richmond, VA, 23261-6609, USA
- SO Journal of Medicinal Chemistry (1991), 34(10), 3011-22 CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

IT 135257-04-4P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn., antihypertensive, and calcium channel blocking activity of)

RN 135257-04-4 CAPLUS

CN Acetamide, N-[[1-[3-(4-acetyl-2-methoxyphenoxy)propyl]-4-piperidinyl]bis(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

=> file Beilstein COST IN U.S. DOLLARS SINCE FILE TOTAL SESSION ENTRY FULL ESTIMATED COST 9.97 605.27 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -1.24 -1.24

FILE 'BEILSTEIN' ENTERED AT 13:07:45 ON 14 NOV 2002 COPYRIGHT (c) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE RELOADED ON OCTOBER 20, 2002

FILE COVERS 1779 TO 2001.
*** FILE CONTAINS 8,374,887 SUBSTANCES ***

- >>> For the revised summary sheet please see:
 http://info.cas.org/ONLINE/DBSS/beilsteinss.html <<<</pre>
- >>> PLEASE NOTE: Reaction and substance documents are stored in different file segments. Use separate queries to search for reaction and substance data. When searching for bibliographic information you have the option to chose the file segment. (Use "/XXX.SUB" to search for a bibliographic term in

substance documents. To restrict the search to reaction documents use "/XXX.RX".)

For additional information see HELP RXS. <<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.

* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *

* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE

* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.

* FOR PRICE INFORMATION SEE HELP COST *************************

=> s 18

SAMPLE SEARCH INITIATED 13:07:57 FILE 'BEILSTEIN' SCREENING

SAMPLE SCREEN SEARCH COMPLETED - 509 TO ITERATE

100.0% PROCESSED 509 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.26

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS:

8828 TO 11532

PROJECTED ANSWERS:

0 TO

L13 0 SEA SSS SAM L8

=> file registry

COST IN U.S. DOLLARS SINCE FILE TOTAL SESSION ENTRY FULL ESTIMATED COST 0.36 605.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL SESSION ENTRY

CA SUBSCRIBER PRICE 0.00 -1.24

FILE 'REGISTRY' ENTERED AT 13:11:37 ON 14 NOV 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

13 NOV 2002 HIGHEST RN 473527-47-8 STRUCTURE FILE UPDATES: DICTIONARY FILE UPDATES: 13 NOV 2002 HIGHEST RN 473527-47-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 9996657iv.str

L14 STRUCTURE UPLOADED

=> d 114 L14 HAS NO ANSWERS L14 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 114

SAMPLE SEARCH INITIATED 13:12:09 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 4976 TO ITERATE

20.1% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 95293 TO 103747
PROJECTED ANSWERS: 0 TO 0

L15 0 SEA SSS SAM L14

=> s l14 ful

FULL SEARCH INITIATED 13:12:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 97373 TO ITERATE

100.0% PROCESSED 97373 ITERATIONS

SEARCH TIME: 00.00.20

L16 9 SEA SSS FUL L14

=> file uspatall

COST IN U.S. DOLLARS SINCE FILE TOTAL

FULL ESTIMATED COST ENTRY SESSION 140.66 746.29

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL

CA SUBSCRIBER PRICE ENTRY SESSION 0.00 -1.24

FILE 'USPATFULL' ENTERED AT 13:12:45 ON 14 NOV 2002 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:12:45 ON 14 NOV 2002 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 116

L17 2 L16

=> d abs bib hitstr 1-2

Print selected from Online session13:16Page 26

ILN

0 ANSWERS

9 ANSWERS

45 - 4,

L17 ANSWER 1 OF 2 USPATFULL

```
A method of treating cardiac dysfunction, the effects of histamine, and
AΒ
       gastric secretion excesses with aryl(alkyl and alkylene)-N-[(phenoxy and
       phenythio) alkyl] aminoheterocyclics corresponding to the formula:
       ##STR1## wherein Ar is phenyl or substituted phenyl; R is phenyl,
       substituted phenyl, pyridinyl or cycloalkyl; A is hydrogen, hydroxy,
       cyano, amido and amino; Q is --CH.sub.2 --, --CH--, or --CHOH--; d and n
       are zero or one and the dotted lines form double bonds consistent with
       the valence of carbon; p is zero, one or two; m is one to six inclusive;
       B is oxygen, nitrogen, sulfur, sulfinyl or sulfonyl; z is zero or one; l
       is zero or one; W is hydrogen, loweralkyl, halo, nitro, loweralkoxy or
       hydroxy; X is hydrogen, loweralkyl, halogen, loweralkoxy or hydroxy; Y
       is --CH(OH)CH.sub.2 OH, --CH(OH)C(O)OH, --C(O)C(O)OH, --C(O)CH.sub.2
       OH, --C(O)C(O)OCH.sub.3, --C(O)C(O)OC.sub.2 H.sub.5, --CH.sub.2
       C(0)OC.sub.2 H.sub.5, --CH(OH)C(O)OCH.sub.3, --CH(OH)C(O)OC.sub.2
       H.sub.5 or --C(O)CH.sub.2 OC(O)CH.sub.3; and the pharmaceutically
       acceptable salts thereof; in addition to the above methods of treatment,
       compounds wherein (B).sub.z is oxygen are useful in a method of treating
       Gell and Coombs type 1 allergic responses in mammals.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN
       91:98390 USPATFULL
ΤI
       Aryl (alkyland alkylene) -N-((phenoxy and phenylthio)alkyl)
       aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and
       antiallergy agents
TN
       Teng, Lina C., Richmond, VA, United States
       Walsh, David A., Richmond, VA, United States
       Shanklin, Jr., James R., Richmond, VA, United States
PA
       A. H. Robins Company, Incorporated, Richmond, VA, United States (U.S.
       corporation)
PΙ
       US 5070087
                               19911203
                               19890508 (7)
AΙ
       US 1989-349247
DCD
       20060307
DT
       Utility
FS
       Granted
EXNAM
      Primary Examiner: Shah, Mukund J.; Assistant Examiner: Ward, E. C.
LREP
       Jackson, Richard K.
CLMN
       Number of Claims: 5
ECL
       Exemplary Claim: 1
DRWN
      No Drawings
LN.CNT 2320
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 135257-00-0P 135257-01-1P
        (prepn. of, as cardiovascular, antihistaminic, antisecretory, and
        antiallergic agent)
RN
     135257-00-0 USPATFULL
CN
     4-Piperidineacetamide, 1-[3-(4-acetyl-2-methoxyphenoxy)propyl]-
       .alpha.,.alpha.-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)
```

$$C = NH_2$$
 $N = (CH_2)_3 = 0$

OMe

RN 135257-01-1 USPATFULL

CN 4-Piperidineacetamide, 1-[3-(4-acetyl-2-methoxyphenoxy)propyl].alpha.,.alpha.-bis(4-fluorophenyl)-, (2E)-2-butenedioate (2:1) (9CI)
(CA INDEX NAME)

CM 1

CM 2

CRN 110-17-8 CMF C4 H4 O4 CDES 2:E

Double bond geometry as shown.

L17 ANSWER 2 OF 2 USPATFULL

AB A method of treating allergy with substituted heterocyclic amines is disclosed wherein the active agents are expressed generally by the formula which includes certain known and certain novel compounds: ##STR1## wherein p is zero, one or two; m is one to six inclusive; A is selected from hydrogen, hydroxy or cyano; d is zero or one; Q is --CH--,

--CH.sub.2 -- or ##STR2## n is zero or one and when Q is --CH-- and n is one, a double bond is formed with one of the adjacent carbons but not both at the same time, and when n and d are zero at the same time, a double bond is formed between the .alpha. carbon and a carbon of the central heterocyclic amine ring; Ar, D and R are selected from phenyl, substituted phenyl, pyridinyl, thienyl, furanyl or naphthyl and in addition, R may have the values benzyl, substituted benzyl, cycloalkyl or loweralkyl and D may additionally have the values:
2H-1-benzopyran-2-one, 4-oxo-4H-1-benzopyran-2-carboxylic acid loweralkyl ester, 2,3-dihydro-4H-1-benzopyran-4-one or 1,4-benzodioxan-loweralkyl-2-yl, and the pharmaceutically acceptable salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 89:17314 USPATFULL

TI Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment

IN Yanni, John M., Chesterfield, VA, United States Walsh, David A., Richmond, VA, United States

PA A. H. Robins Company, Incorporated, Richmond, VA, United States (U.S.

corporation)

PI US 4810713 19890307 AI US 1985-811799 19851220 (6)

DT Utility FS Granted

EXNAM Primary Examiner: Schenkman, Leonard

CLMN Number of Claims: 101 ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3420

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 111951-79-2P 111951-80-5P 111951-81-6P 111951-89-4P 111952-11-5P 111952-12-6P

(prepn. of, as antihypertensive or antianginal agent)

RN 111951-79-2 USPATFULL

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ &$$

RN 111951-80-5 USPATFULL

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ &$$

Print selected from Online session13:16Page 29

RN 111951-81-6 USPATFULL

CN 3-Piperidinepropanamide, 1-[3-(4-acetyl-2-methoxyphenoxy)propyl].alpha.,.alpha.-diphenyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & \\ \text{OMe} & & \\ \end{array}$$

RN 111951-89-4 USPATFULL

CN 3-Piperidinepropanamide, 1-[2-(2,6-dichlorophenoxy)ethyl]-.alpha.,.alpha.diphenyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} C1 & & Ph \\ \hline \\ O-CH_2-CH_2-N & CH_2-C-NH_2 \\ \hline \\ C1 & & Ph \end{array}$$

RN 111952-11-5 USPATFULL

CN 4-Piperidineacetamide, 1-[3-(4-acetyl-2-methoxyphenoxy)propyl].alpha.,.alpha.-diphenyl-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 111951-79-2 CMF C31 H36 N2 O4

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ &$$

CM 2

CRN 110-17-8 CMF C4 H4 O4 CDES 2:E

Double bond geometry as shown.

Print selected from Online session13:16Page 30

RN 111952-12-6 USPATFULL

CN 4-Piperidineacetamide, 1-[4-(4-acetyl-2-methoxyphenoxy)butyl].alpha.,.alpha.-diphenyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 111951-80-5 CMF C32 H38 N2 O4

Ac O-
$$(CH_2)_4$$
 N Ph O Ph O

CM 2

CRN 110-17-8 CMF C4 H4 O4 CDES 2:E

Double bond geometry as shown.

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	15.02	761.31
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
The second second of the secon	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.24

FILE 'CAPLUS' ENTERED AT 13:14:44 ON 14 NOV 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA´Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Nov 2002 VOL 137 ISS 20 FILE LAST UPDATED: 13 Nov 2002 (20021113/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d his

(FILE 'HOME' ENTERED AT 12:32:11 ON 14 NOV 2002)

FILE 'REGISTRY' ENTERED AT 12:32:23 ON 14 NOV 2002

L1 STRUCTURE UPLOADED

L2 11 S L1

L3 8140 S L1 FUL

L4 STRUCTURE UPLOADED

L5 5 S L4

L6 2225 S L5 FUL

FILE 'USPATFULL, USPAT2' ENTERED AT 12:52:35 ON 14 NOV 2002

L7 425 S L6

FILE 'REGISTRY' ENTERED AT 13:03:20 ON 14 NOV 2002

L8 STRUCTURE UPLOADED

L9 0 S L8

L10 3 S L8 FUL

FILE 'USPATFULL, USPAT2' ENTERED AT 13:04:26 ON 14 NOV 2002

L11 8 S L10

FILE 'CAPLUS' ENTERED AT 13:05:57 ON 14 NOV 2002

L12 2 S L10

FILE 'BEILSTEIN' ENTERED AT 13:07:45 ON 14 NOV 2002

L13 0 S L8

FILE 'REGISTRY' ENTERED AT 13:11:37 ON 14 NOV 2002

L14 STRUCTURE UPLOADED

L15 0 S L14

L16 9 S L14 FUL

FILE 'USPATFULL, USPAT2' ENTERED AT 13:12:45 ON 14 NOV 2002

L17 2 S L16

FILE 'CAPLUS' ENTERED AT 13:14:44 ON 14 NOV 2002

=> s 116

L18 6 L16

=> d abs bib hitstr 1-6

L18 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2002 ACS

GΙ

Title compds. I [Ar = (substituted) Ph; R = (substituted) Ph, -benzyl, pyridyl, pyridylmethyl, cycloalkyl, cycloalkylmethyl; A = H, OH, cyano, CONR4R5, NR4R5; Q = CH2, CH, CHOH; d, n = 0, 1; dotted lines = optional bonds; p = 0-2; m = 0-6; B = O, N, S, SO, SO2; z = 0, 1 (m = 2-6 when z = 1); l = 0, 1; W = H, C1-8 alkyl, halo, NO2, C1-8 alkoxy, OH; X = H, C1-8 alkyl, halo, C1-8 alkoxy, OH; Y = CHOHCH2OH, CHOHCO2H, COCO2H, COCH2OH, COCO2Me, COCO2Et, CH2CO2Et, CH2CO2Et, CHOHCO2Me, CHOHCO2Et, COCH2OCOMe; R1-R3 = H, C1-8 alkyl, halo, NO2, CF3, cyano, C1-8 alkoxy, OH; R4, R5 = H, (phenyl) C1-8 alkyl, Ph] were prepd., e.g., as antiallergics (no data). Thus, benzyl 4-hydroxy-3-methyoxymandelate (prepn. given) was O-alkylated by Br(CH2)3Cl and the product formed was treated with [.alpha.,.alpha.-bis(4-fluorophenyl)]-4-piperidinemethanol hydrochloride (prepn. given). The resultant benzyl ester was hydrogenated over 5% Pd/C to give title compd. II.

AN 1992:151575 CAPLUS

DN 116:151575

TI Preparation of N-phenoxyalkyl(aralkyl)piperidines and related compounds as cardiovascular, anthihistaminic, antisecretory, and antiallergy agents

IN Teng, Lina C.; Walsh, David A.; Shanklin, James R., Jr.

PA Robins, A. H., Co., Inc., USA

SO U.S., 34 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

OS MARPAT 116:151575

IT 135257-00-0P 135257-01-1P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as cardiovascular, antihistaminic, antisecretory, and antiallergic agent)

RN 135257-00-0 CAPLUS

CN 4-Piperidineacetamide, 1-[3-(4-acetyl-2-methoxyphenoxy)propyl]-.alpha.,.alpha.-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)

$$C = NH_2$$
 $N = (CH_2)_3 = 0$

OMe

RN 135257-01-1 CAPLUS

CN 4-Piperidineacetamide, 1-[3-(4-acetyl-2-methoxyphenoxy)propyl].alpha.,.alpha.-bis(4-fluorophenyl)-, (2E)-2-butenedioate (2:1) (9CI) (CA
INDEX NAME)

CM 1

CRN 135257-00-0 CMF C31 H34 F2 N2 O4

$$C = NH_2$$
 $N = (CH_2)_3 = 0$

OMe

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

L18 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2002 ACS GI

$$\begin{bmatrix} \text{F} & \text{CH} & \text{CH}_2 \\ \text{n} & \text{CH}_2 \end{bmatrix}_n - \text{Y} & \begin{bmatrix} \text{R}^2 \\ \text{R}^3 & \text{II} \end{bmatrix}$$

$$\begin{bmatrix} \text{F} & \text{CN} & \text{CH}_2 \text{ } \\ \text{C} & \text{(CH}_2 \text{) } \\ \text{m} & \text{(CH}_2 \text{) } \\ \text{n} & \text{MeO} \end{bmatrix}$$

AB Title compds. I (R = 4-F, H, 3,4-F2, 2,4-F2, 4-Cl, 4-Me, 3-F, 4-MeO, R1 = 4-FC6H4, Ph, 3-FC6H4, H, 2-pyridyl, etc., X = CH, CHCH2, COHC, etc., R1 = 2-6, II [R2 = 2-MeO, R3 = 4-COMe, 4-CH(OH)Me, 4-Et, 4-CO2Me, etc.; R2 = 4-COMe, 4-CONH2, 4-cyano, 4-F, etc., R3 = H; Y = 0, CH2, NMe, S, SO2, R1 = 2, 3], and III (R1 = 1, 2, R1 = 0, 1; ring position = 3, 4) were prepd. as calcium-channel blockers and antihypertensive agents. Thus, reacting Me vanillate with 4-[bis(4-fluorophenyl)methyl]-1-(3-chloropropyl)piperidine gave II (R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R3 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y = 0, R1 = 2-MeO, R1 = 4-CO2Me, Y =

Ι

III

AN 1991:583028 CAPLUS

DN 115:183028

TI Synthesis, calcium-channel-blocking activity, and antihypertensive activity of 4-(diarylmethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds

AU Shanklin, James R., Jr.; Johnson, Christopher P., III; Proakis, Anthony G.; Barrett, Richard J.

CS Dep. Chem. Res., A. H. Robins Co., Richmond, VA, 23261-6609, USA

SO Journal of Medicinal Chemistry (1991), 34(10), 3011-22 CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

IT 135257-01-1P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn., antihypertensive, and calcium channel blocking activity of)

RN 135257-01-1 CAPLUS

CN 4-Piperidineacetamide, 1-[3-(4-acetyl-2-methoxyphenoxy)propyl].alpha.,.alpha.-bis(4-fluorophenyl)-, (2E)-2-butenedioate (2:1) (9CI) (CA
INDEX NAME)

CM 1

CRN 135257-00-0 CMF C31 H34 F2 N2 O4

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

L18 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2002 ACS

HOCRR1 N (CH₂) nO
$$\mathbb{R}^{3}$$
 R²

AB A series of title piperidines I (R, R1 = substituted phenyl) were synthesized and evaluated for antiallergy activity. Several analogs had potent activity in the passive foot anaphylaxis assay, an IgE-mediated model useful in the detection of compds. possessing antiallergic activity. In particular, I (R = R1 = 4-FC6H4; R2 = 2-MeO, R3 = 4-Ac) (AHR-5333) was more potent than oxatomide and terfenadine in this assay.

AN 1989:38844 CAPLUS

DN 110:38844

TI Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl)piperidines and structurally related compounds

AU Walsh, David A.; Franzyshen, Stephen K.; Yanni, John M.

CS Dep. Chem. Res., A. H. Robins Co., Richmond, VA, 23261-6609, USA

SO Journal of Medicinal Chemistry (1989), 32(1), 105-18 CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

OS CASREACT 110:38844

IT 111951-79-2P 111952-11-5P

RN 111951-79-2 CAPLUS

Ac OMe

4-Piperidineacetamide, 1-[3-(4-acetyl-2-methoxyphenoxy)propyl].alpha.,.alpha.-diphenyl- (9CI) (CA INDEX NAME)

Ph

C C-NH2
Ph

OMe

RN 111952-11-5 CAPLUS

CN 4-Piperidineacetamide, 1-[3-(4-acetyl-2-methoxyphenoxy)propyl].alpha.,.alpha.-diphenyl-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 111951-79-2 CMF C31 H36 N2 O4

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ &$$

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

L18 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2002 ACS GI

Print selected from Online session13:16Page 37

```
The title compds. I [A = H, OR1, cyano, CONR1R2, COR1, CO2R1, R1CO2,
AB
     CH2OR1, CH2NR1R2; Ar = pyridyl, thienyl, furyl, naphthyl, (un)substituted
     Ph; B = O, S, SO, SO2, NR1, NCO2R1; D = Ar, benzopyranyl,
    benzodioxanylalkyl, quinolinyl; Q = CH, CH2, CH0H; R = Ar, (un)substituted
     PhCH2; R1 = H, R2; R2 = alkyl, Ph, phenylalkyl; d, n, z = 0, 1 (n + z
     .noteq. 0); m = 0-6; p = 0-2] were prepd. as antihypertensives and
     antianginal agents. A mixt. of 4.75 g 4-[.alpha.,.alpha.-bis(p-
     fluorophenyl)methyl]piperidine and 4.0 g 3-(p-acetyl-o-
    methoxyphenoxy) propyl chloride (prepn. each given) in DMF contg. NaHCO3
    was heated at 100.degree. for 1 h to give 5.5 g disubstituted piperidine
     II which, at 10-7 M, caused a 100% redn. in contraction of rabbit aortal
     strips exposed to 10-3 M Ca.
AN
     1988:37654 CAPLUS
DN
    108:37654
    Preparation of N-aryloxyalkyl arylalkyl- and arylalkylenepiperidines as
тT
     antihypertensives and antianginal agents
IN
     Shanklin, James Robert, Jr.; Proakis, Anthony George
PA
    Robins, A. H., Co., Inc., USA
    S. African, 184 pp.
SO
     CODEN: SFXXAB
DТ
    Patent
LA
    English
FAN.CNT 3
    PATENT NO.
                   KIND DATE
                                       APPLICATION NO. DATE
     -----
                                        _____
                                                        -----
                   A 19870225
A 19881210
PΙ
    ZA 8604522
                                       ZA 1986-4522
                                                        19860617
    IN 163948
                                        IN 1986-MA407
                                                        19860527
                    A1 19900429
    IL 78939
                                         IL 1986-78939
                                                        19860527
                    A2 19870725
    JP 62169763
                                         JP 1986-169673 19860718
                    B4 19950802
    JP 07072171
                    Α
                         19870718
    DK 8603479
                                         DK 1986-3479
                                                         19860722
    AU 8662473
                    A1 19870723
                                         AU 1986-62473
                                                         19860909
    AU 594972
                    B2
                         19900322
    EP 228893 A2 19870715
EP 228893 A3 19900103
                                        EP 1986-310047 19861222
                    A3 19900103
        R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE
    EP 235463 A2 19870909
                                       EP 1986-310045 19861222
    EP 235463
                     A3
                          19900117
        R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE
    CA 1291995 A1 19911112
                                       CA 1987-526931 19870108
    AU 8929823
                     A1
                          19890810
                                        AU 1989-29823
                                                        19890210
    AU 629535
                    B2
                          19921008
                    A 199010
19860117
                          19901031
    ZA 8901081
                                        ZA 1989-1081
                                                        19890210
PRAI US 1986-819701
    US 1988-154390
                          19880210
    US 1985-811799
                          19851220
    ZA 1986-4522
                          19860617
IT
    111951-79-2P 111951-80-5P 111951-81-6P
    111951-89-4P 111952-11-5P 111952-12-6P
    RL: SPN (Synthetic preparation); PREP (Preparation)
       (prepn. of, as antihypertensive or antianginal agent)
RN
    111951-79-2 CAPLUS
CN
    4-Piperidineacetamide, 1-[3-(4-acetyl-2-methoxyphenoxy)propyl]-
     .alpha.,.alpha.-diphenyl- (9CI) (CA INDEX NAME)
```

$$\begin{array}{c|c} O-(CH_2)_3-N & Ph \\ OMe & C-NH_2 \\ Ph & O \end{array}$$

RN 111951-80-5 CAPLUS

CN 4-Piperidineacetamide, 1-[4-(4-acetyl-2-methoxyphenoxy)butyl]-.alpha.,.alpha.-diphenyl- (9CI) (CA INDEX NAME)

RN 111951-81-6 CAPLUS

CN 3-Piperidinepropanamide, 1-[3-(4-acetyl-2-methoxyphenoxy)propyl]-.alpha.,.alpha.-diphenyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Ph O} \\ & \parallel \\ & \parallel \\ \text{CH}_2 - \text{C-C-NH}_2 \\ & \parallel \\ & \text{Ph} \end{array}$$

RN 111951-89-4 CAPLUS

CN 3-Piperidinepropanamide, 1-[2-(2,6-dichlorophenoxy)ethyl]-.alpha.,.alpha.diphenyl- (9CI) (CA INDEX NAME)

RN 111952-11-5 CAPLUS

CN 4-Piperidineacetamide, 1-[3-(4-acetyl-2-methoxyphenoxy)propyl].alpha.,.alpha.-diphenyl-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 111951-79-2 CMF C31 H36 N2 O4

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ &$$

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 111952-12-6 CAPLUS

CN 4-Piperidineacetamide, 1-[4-(4-acetyl-2-methoxyphenoxy)butyl].alpha.,.alpha.-diphenyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 111951-80-5 CMF C32 H38 N2 O4

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

L18 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2002 ACS GI

Q1= N
$$\sim$$
 NR4 Q2= NR3 \sim N Q3= N \sim N \sim CN \sim CN \sim NR4 Q2= NR3 \sim NR4 Q2= NR3 \sim NR4 \sim NR4

AB R10CH2CH(OH) CH2Z(CO) nR2 [I; R1 = (un) substituted (hetero) aryl; R2 = (hetero) aryl, cycloalkyl, substituted alkyl; Z = NR3(CH2) nNR4, Q1, Q2, Q3; R3 = H, alkyl; R4 = H, alkyl, (un) substituted Ph; n = 0, 1 m = 2-4] were prepd. as cardiotonics (no data). Thus, (S)-2,2-dimethyl-1,3-dioxolane-4-methanol was sequentially benzylated deketalized, tosylated, and condensed with 4-hydroxy-1H-indole-2-carboxamide to give (R)-4-propoxyindole II [R5 = PhCH2OCH2CH(OH), R6 = CONH2]. This was debenzylated, epoxidized, and dehydrated to give (S)-II (R5 = oxiranyl, R6 = cyano). The latter was condensed with 1-(di-3-thienylmethyl)piperazine to give (S)-(indolyloxy)hydroxypropylpiperazine III.

AN 1987:84635 CAPLUS

DN 106:84635

TI (Aryloxy) hydroxypropyl heterocycles

IN Berthold, Richard; Ott, Hans

PA Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.

SO Ger. Offen., 60 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

FAN. CNI 2					
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
					
PΙ	DE 3524955	A1	19860130	DE 1985-3524955	19850712
	GB 2163150	A1	19860219	GB 1985-17068	19850705
	GB 2163150	B2	19880525		
	CH 665208	Α	19880429	CH 1985-2985	19850710
	BE 902897	A1	19860115	BE 1985-11297	19850715
	JP 61037765	A2	19860222	JP 1985-160011	19850718
PRAI	DE 1984-3426630		19840719		
	DE 1984-3426632		19840719		
	DE 1985-3509557		19850316		
OS	CASPEACT 106.946	2.5			

OS CASREACT 106:84635

IT 103915-02-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as cardiotonic)

RN 103915-02-2 CAPLUS

CN Benzeneacetamide, N-[1-[3-[(1',3'-dihydro-1'-oxospiro[cyclohexane-1,2'-[2H]inden]-4'-yl)oxy]-2-hydroxypropyl]-4-piperidinyl]-.alpha.-phenyl-(9CI) (CA INDEX NAME)

L18 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2002 ACS

AB The title compds. R1OCH2CH(OH)CH2Z(CO)mR [R = (un)substituted alkyl; R1 = arom. or heteroarom. radical; Z = piperidinylamino, 4-piperazinylamino, NR2(CH2)nNR3; R2, R3 = H, alkyl; n = 2-4] are prepd. as cardiotonic, antiarrhythmic, and .alpha.- and .beta.-sympatholytics. Thus, melting a mixt. of (S)-4-(2,3-epoxypropoxy)-1H-indole-2-carbonitrile (prepn. given) with 1-(3,3'-dithienylmethyl)piperazine (prepn. given) gave (S)-4-[3-[4-(3,3'-dithienylmethyl)piperazin-1-yl]-2-hydroxypropoxy]-1H-indole-2-carbonitrile (I). I (10-9-10-6M) inhibited the pos. inotropic effect of adrenaline on the guinea pig auricle, in vitro.

AN 1986:572505 CAPLUS

DN 105:172505

TI 3-Aminopropoxyaryl derivatives

IN Berthold, Richard; Ott, Hans

PA Sandoz S. A., Switz.

SO Fr. Demande, 57 pp. CODEN: FRXXBL

DT Patent

LA French

FAN CNT 2

FAN.	CNT 2				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ΡI	FR 2567885	A1	19860124	FR 1985-10852	19850712
	FR 2567885	B1	19880916		
	GB 2163150	A1	19860219	GB 1985-17068	19850705
	GB 2163150	B2	19880525		
	CH 665208	Α	19880429	CH 1985-2985	19850710
	BE 902897	A1	19860115	BE 1985-11297	19850715
	JP 61037765	A2	19860222	JP 1985-160011	19850718
PRAI	DE 1984-3426630		19840719		
	DE 1984-3426632		19840719		
	DE 1985-3509557		19850316		
IT	104546-41-0P				

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as cardiotonic drug) RN 104546-41-0 CAPLUS

LN.CNT 1625

. افره ۱

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 414866-81-2P

(drug; prepn. of piperidine derivs. useful for treating multidrug resistance and compns. thereof)

RN 414866-81-2 USPATFULL

CN 4-Piperidinecarboxamide, 1-[2-hydroxy-3-(3,4,5-trimethoxyphenoxy)propyl]-N[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

IT 414866-86-7P

(drug; prepn. of piperidine derivs. useful for treating multidrug resistance and compns. thereof)

RN 414866-86-7 USPATFULL

CN 3-Piperidinecarboxamide, 1-[(2R)-2-hydroxy-3-(3,4,5trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 6 OF 8 USPATFULL

AB Substituted heterocyclic compounds are disclosed. The compounds are useful for treating multidrug resistance. The compounds can be formulated in compositions with a carrier and, optionally, a therapeutic agent. One suitable substituted heterocyclic compound has the formula: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:186292 USPATFULL

TI Substituted heterocyclic compounds for treating multidrug resistance

IN Degenhardt, Charles Raymond, Cincinnati, OH, UNITED STATES

Eickhoff, David Joseph, Edgewood, KY, UNITED STATES

PA The Procter Gamble Co. (U.S. corporation)

PI US 2002099215 A1 20020725

 \sim

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1612RXD

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
NEWS
                 Web Page URLs for STN Seminar Schedule - N. America
NEWS
         Apr 08
                 "Ask CAS" for self-help around the clock
        Apr 09
                 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS
     4 Apr 09
NEWS
                 ZDB will be removed from STN
NEWS
     5 Apr 19
                 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6
        Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7
         Apr 22
                 BIOSIS Gene Names now available in TOXCENTER
NEWS 8
        Apr 22
                 Federal Research in Progress (FEDRIP) now available
         Jun 03
NEWS 9
                New e-mail delivery for search results now available
NEWS 10 Jun 10
                 MEDLINE Reload
NEWS 11 Jun 10
                 PCTFULL has been reloaded
NEWS 12
        Jul 02
                 FOREGE no longer contains STANDARDS file segment
NEWS 13
        Jul 22
                 USAN to be reloaded July 28, 2002;
                 saved answer sets no longer valid
NEWS 14
         Jul 29
                 Enhanced polymer searching in REGISTRY
NEWS 15
        Jul 30
                 NETFIRST to be removed from STN
NEWS 16 Aug 08
                 CANCERLIT reload
NEWS 17
         Aug 08
                 PHARMAMarketLetter (PHARMAML) - new on STN
NEWS 18
        Aug 08
                 NTIS has been reloaded and enhanced
NEWS 19 Aug 19
                 Aquatic Toxicity Information Retrieval (AQUIRE)
                 now available on STN
NEWS 20
                 IFIPAT, IFICDB, and IFIUDB have been reloaded
        Aug 19
NEWS 21
         Aug 19
                 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22
        Aug 26
                 Sequence searching in REGISTRY enhanced
NEWS 23
         Sep 03
                 JAPIO has been reloaded and enhanced
NEWS 24
        Sep 16
                 Experimental properties added to the REGISTRY file
NEWS 25
                 Indexing added to some pre-1967 records in CA/CAPLUS
         Sep 16
NEWS 26
                 CA Section Thesaurus available in CAPLUS and CA
        Sep 16
NEWS 27
        Oct 01
                CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28
        Oct 21 EVENTLINE has been reloaded
NEWS 29
        Oct 24
                BEILSTEIN adds new search fields
NEWS 30
        Oct 24
                Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31 Oct 25
                MEDLINE SDI run of October 8, 2002
             October 14 CURRENT WINDOWS VERSION IS V6.01,
NEWS EXPRESS
              CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
              AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS INTER
              General Internet Information
NEWS LOGIN
              Welcome Banner and News Items
NEWS PHONE
              Direct Dial and Telecommunication Network Access to STN
NEWS WWW
              CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:32:11 ON 14 NOV 2002

=> file registry
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 12:32:23 ON 14 NOV 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 NOV 2002 HIGHEST RN 473527-47-8 DICTIONARY FILE UPDATES: 13 NOV 2002 HIGHEST RN 473527-47-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

Uploading 9996657iv.str

L1 STRUCTURE UPLOADED

=> d l1 L1 HAS NO ANSWERS L1 ST



G1 O, N

G2 C, N

G3 H, OH

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:32:46 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 36942 TO ITERATE

2.7% PROCESSED 1000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED) SEARCH TIME: 00.00.03

11 ANSWERS

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**

BATCH **INCOMPLETE**

PROJECTED ITERATIONS:

727403 TO 750277

PROJECTED ANSWERS:

6918 TO 9336

L2

11 SEA SSS SAM L1

=> d 1-5

L2 ANSWER 1 OF 11 REGISTRY COPYRIGHT 2002 ACS

RN 352641-87-3 REGISTRY

CN 1-Piperidineethanol, .alpha.-[[4-(1-hydroxypropyl)-2-methoxyphenoxy]methyl]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C18 H29 N O4

SR Chemical Library

LC STN Files: CHEMCATS

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- L2 ANSWER 2 OF 11 REGISTRY COPYRIGHT 2002 ACS
- RN 300852-45-3 REGISTRY
- CN 1-Piperidineethanol, .alpha.-[(2,4,6-trimethylphenoxy)methyl]- (9CI) (CA INDEX NAME)
- FS 3D CONCORD
- MF C17 H27 N O2
- CI COM
- SR Chemical Library
- LC STN Files: CHEMCATS

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- L2 ANSWER 3 OF 11 REGISTRY COPYRIGHT 2002 ACS
- RN 295317-30-5 REGISTRY
- CN 6-Isoquinolinol, 1,2,3,4-tetrahydro-2-(1-methylethyl)-1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
- MF C26 H36 N2 O2 . C2 H F3 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 295317-29-2 CMF C26 H36 N2 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

- 2 REFERENCES IN FILE CA (1962 TO DATE)
- 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)
- L2 ANSWER 4 OF 11 REGISTRY COPYRIGHT 2002 ACS
- RN 256372-47-1 REGISTRY
- CN 1-Piperidineethanol, .alpha.-[(4-ethylphenoxy)methyl]-4-hydroxy-4-(3-quinolinyl)-, (.alpha.S)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
- FS STEREOSEARCH
- MF C25 H30 N2 O3 . C2 H2 O4
- SR CA
- LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 256372-46-0 CMF C25 H30 N2 O3

Absolute stereochemistry.

CM 2

CRN 144-62-7 CMF C2 H2 O4

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 5 OF 11 REGISTRY COPYRIGHT 2002 ACS

RN 247189-71-5 REGISTRY

CN Methanone, [5,6-dihydro-3-methoxy-9-(4-methoxyphenyl)indolo[2,1-a]isoquinolin-12-yl][3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C38 H38 N2 O4

SR CA

LC STN Files: CA, CAPLUS

$$\begin{array}{c} \text{MeO} \\ \text{O} \\ \text{C} \\ \text{OMe} \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)

Print selected from Online session13:16Page 6

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 12:32:11 ON 14 NOV 2002)

FILE 'REGISTRY' ENTERED AT 12:32:23 ON 14 NOV 2002

L1 STRUCTURE UPLOADED

11 S L1 L2

=> s l1 ful

FULL SEARCH INITIATED 12:35:04 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 734911 TO ITERATE

54.4% PROCESSED 400000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.41

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**

BATCH **INCOMPLETE**

8140 ANSWERS

PROJECTED ITERATIONS: 734911 TO 734911

PROJECTED ANSWERS: 14589 TO 15321

L3 8140 SEA SSS FUL L1

Uploading 9996657iv.str


L4 STRUCTURE UPLOADED

=> d 14

L4 HAS NO ANSWERS

STR





G1 O, N

G2 C,N

G3 H,OH

Structure attributes must be viewed using STN Express query preparation.

=> s 14

SAMPLE SEARCH INITIATED 12:47:19 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 16513 TO ITERATE

6.1% PROCESSED 1000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED) SEARCH TIME: 00.00.02

5 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS:

322579 TO 337941

PROJECTED ANSWERS:

1106 TO 2196

L5

5 SEA SSS SAM L4

=> s 15 ful

FULL SEARCH INITIATED 12:48:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 326548 TO ITERATE

100.0% PROCESSED 326548 ITERATIONS

2225 ANSWERS

SEARCH TIME: 00.00.31

L6 2225 SEA SSS FUL L4

=> file uspatall
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST

300.62 300.83

FILE 'USPATFULL' ENTERED AT 12:52:35 ON 14 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:52:35 ON 14 NOV 2002 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 16

L7 425 L6

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE Do you want to switch to the Registry File? Choice (Y/n):

Switching to the Registry File ...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST

110.78 411.61

FILE 'REGISTRY' ENTERED AT 13:03:20 ON 14 NOV 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 NOV 2002 HIGHEST RN 473527-47-8 DICTIONARY FILE UPDATES: 13 NOV 2002 HIGHEST RN 473527-47-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 9996657iv.str

L8 STRUCTURE UPLOADED

=> d 18 L8 HAS NO ANSWERS L8 STR

Print selected from Online session13:16Page 9

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 18

SAMPLE SEARCH INITIATED 13:03:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5243 TO ITERATE

19.1% PROCESSED 1000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS:

ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS:

100521 TO 109199

PROJECTED ANSWERS: 0 TO

Г9

O SEA SSS SAM L8

=> s 18 ful

FULL SEARCH INITIATED 13:03:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 103619 TO ITERATE

100.0% PROCESSED 103619 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.22

L10

3 SEA SSS FUL L8

=> file uspatall

COST IN U.S. DOLLARS

SINCE FILE ENTRY TOTAL

FULL ESTIMATED COST

140.66

SESSION 552.27

FILE 'USPATFULL' ENTERED AT 13:04:26 ON 14 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:04:26 ON 14 NOV 2002 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 110

L11

8 L10

=> d abs bib hitstr 1-8

L11 ANSWER 1 OF 8 USPATFULL

AB Substituted heterocyclic compounds for treating multidrug resistance are disclosed. Compositions and methods of use for the substituted heterocyclic compounds are disclosed. Suitable substituted heterocyclic compounds include: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:236071 USPATFULL

TI Substituted heterocyclic compounds for treating multidrug resistance

IN Degenhardt, Charles Raymond, Cincinnati, OH, UNITED STATES

Eickhoff, David Joseph, Edgewood, KY, UNITED STATES

PI US 2002128269 A1 20020912

AI US 2000-740387 A1 20001219 (9)

PRAI US 2000-241127P

20001017 (60)

DT Utility

FS APPLICATION

LREP THE PROCTER & GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, MINTON HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CANCIDMATI

OH, 45224

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1996

CAS INDEXING IS AVAILABLE FOR THIS PATENT

IT 414866-81-2P

(drug; prepn. of piperidine derivs. useful for treating multidrug resistance and compns. thereof)

RN 414866-81-2 USPATFULL

CN 4-Piperidinecarboxamide, 1-[2-hydroxy-3-(3,4,5-trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

IT 414866-86-7P

(drug; prepn. of piperidine derivs. useful for treating multidrug resistance and compns. thereof)

RN 414866-86-7 USPATFULL

CN 3-Piperidinecarboxamide, 1-[(2R)-2-hydroxy-3-(3,4,5-trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

MeO OH N
$$(CH_2)_3$$
 Ph OMe

L11 ANSWER 2 OF 8 USPATFULL

AB Substituted heterocyclic compounds for treating multidrug resistance are disclosed. Compositions and methods of use for the substituted heterocyclic compounds are disclosed. Suitable substituted heterocyclic compounds include: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT. AN 2002:228337 USPATFULL ΤI

SUBSTITUTED PIPERAZINE COMPOUNDS OPTIONALLY CONTAINING A QUINOLYL MOIETY

FOR TREATING MULTIDRUG RESISTANCE

Degenhardt, Charles Raymond, Cincinnati, OH, UNITED STATES IN

Eickhoff, David Joseph, Edgewood, KY, UNITED STATES

PΙ

AΙ

PRAI

DΤ

FS

APPLICATION
THE PROCTER & GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, WINTON
HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CINCINNATI,
OH, 45224
Number of Claims: 26
Exemplary Claim: 1
No Drawings
2075 LREP

CLMN ECL

DRWN

LN.CNT 2075

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

414866-81-2P

(drug; prepn. of piperidine derivs. useful for treating multidrug resistance and compns. thereof)

414866-81-2 USPATFULL RN

4-Piperidinecarboxamide, 1-[2-hydroxy-3-(3,4,5-trimethoxyphenoxy)propyl]-N-CN [4-phenyl-1-(3-phenylpropyl)butyl] - (9CI) (CA INDEX NAME)

TТ 414866-86-7P

> (drug; prepn. of piperidine derivs. useful for treating multidrug resistance and compns. thereof)

RN 414866-86-7 USPATFULL

CN3-Piperidinecarboxamide, 1-[(2R)-2-hydroxy-3-(3,4,5trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

MeO OH N
$$(CH_2)_3$$
 Ph OMe

L11 ANSWER 3 OF 8 USPATFULL

AB Substituted acyclic compounds are disclosed. The compounds are useful for treating multidrug resistance. The compounds can be formulated in compositions with a carrier and, optionally, a therapeutic agent. One suitable substituted acyclic compound has the formula: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:221836 USPATFULL

TI Acyclic compounds and methods for treating multidrug resistance

IN Degenhardt, Charles Raymond, Cincinnati, OH, UNITED STATES

Eickhoff, David Joseph, Edgewood, KY, UNITED STATES

PI US 2002119979 A1 20020829

AI US 2000-741588 A1 20001219 (9)

PRAI US 2000-241127P 20001017 (60)

DT Utility

FS APPLICATION

LREP THE PROCTER & GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, WINTON HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CINCINNATI, OH, 45224

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1958

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 414866-81-2P

(drug; prepn. of piperidine derivs. useful for treating multidrug resistance and compns. thereof)

RN 414866-81-2 USPATFULL

CN 4-Piperidinecarboxamide, 1-[2-hydroxy-3-(3,4,5-trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

IT 414866-86-7P

(drug; prepn. of piperidine derivs. useful for treating multidrug

resistance and compns. thereof)

RN 414866-86-7 USPATFULL

CN 3-Piperidinecarboxamide, 1-[(2R)-2-hydroxy-3-(3,4,5trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

MeO OH N
$$(CH_2)_3$$
 Ph OMe

L11 ANSWER 4 OF 8 USPATFULL

AB Compounds, compositions, and methods for treating multidrug resistance are disclosed. Suitable compounds are 2-substituted heterocyclic compounds. An example compound has the formula: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:221817 USPATFULL

TI Substituted piperidine amides and methods of their use

IN Degenhardt, Charles Raymond, Cincinnati, OH, UNITED STATES
Eickhoff, David Joseph, Edgewood, KY, UNITED STATES

PI US 2002119960 A1 20020829

AI US 2000-741272 A1 20001219 (9)

PRAI US 2000-241127P 20001017 (60)

DT Utility

FS APPLICATION

LREP THE PROCTER & GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, WINTON HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CINCINNATI, OH, 45224

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1811

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 414866-81-2P

(drug; prepn. of piperidine derivs. useful for treating multidrug resistance and compns. thereof)

RN 414866-81-2 USPATFULL

CN 4-Piperidinecarboxamide, 1-[2-hydroxy-3-(3,4,5-trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

TT 414866-86-7P

(drug; prepn. of piperidine derivs. useful for treating multidrug resistance and compns. thereof)

414866-86-7 USPATFULL RN

CN 3-Piperidinecarboxamide, 1-[(2R)-2-hydroxy-3-(3,4,5trimethoxyphenoxy)propyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

MeO
$$OH$$
 N H N $CH_2)_3$ Ph OMe

ANSWER 5 OF 8 USPATFULL L11

AB Compounds having heterocyclic groups containing two nitrogen atoms are disclosed. The compounds are useful for treating multidrug resistance. The compounds can be formulated in compositions with a carrier and, optionally, a therapeutic agent. One suitable compound has the formula: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN2002:214271 USPATFULL

1002> Compounds having heterocyclic groups containing two nitrogen atoms for TItreating multidrug resistance

IN Degenhardt, Charles Raymond, Cincinnati, OH, UNITED STATES Eickhoff, David Joseph, Edgewood, KY, UNITED STATES

ΡI US 2002115659 Α1 20020822

AΙ US 2000-740644 20001219 (9) Α1

PRAI US 2000-241127P 20001017 (60)

DT Utility

FS APPLICATION

LREP THE PROCTER & GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, WINTON HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CINCINNATI, OH, 45224

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

Print selected from Online session13:16Page 15